Amanda Corbel
Manager, Communications Office
Email amanda.corbel@nih.gov or call 301-228-4489 for all media related questions.
Unpacking the diversity among KRAS mutants
From KRAS G12D to KRAS G12R, new research uncovers how each mutation drives pancreatic cancer differently—and why it matters for patient outcomes.POSTED: 11/19/2025
The allele-specific lipid sensing of KRAS mutants
KRAS mutants don’t just anchor to membranes—they choose their lipid partners. Discover how this specificity could unlock new cancer therapies.POSTED: 7/8/2025
Therapeutic strategies to overcome KRAS (OFF) inhibitors resistance
Understanding and overcoming resistance to KRAS G12C inhibitors remains a key focus in the fight against RAS-driven cancers. Experts describe non-genetic methods of resistance to G12C inhibitors that bind to the inactive, GDP-bound form of the protein, and propose the best therapeutic strategy.POSTED: 9/26/2024
MAP2K4: New kid on the MAP Kinase block
Post-doc Robin A Jansen and her advisor Rene Bernards lay out a compelling argument for MAP2K4 inhibition as an effective combination therapy with RAS-targeted drugs.POSTED: 6/18/2024
AI-generated protein biosensors enable quantitative measurements of endogenous RAS activity in live cells
Measuring active RAS levels in live cells has long been a challenge—until now. Discover how AI-designed biosensors reveal where and how Ras signals inside cells, reshaping cancer research.POSTED: 4/30/2024
Top-Down Proteomics Reveals the KRAS Proteoform Landscape in Colorectal Cancer
Learn about how top-down proteomics uncovered novel KRAS proteoforms, and how this gives us a better understanding of colorectal cancer.POSTED: 3/24/2024
Development of Mutant KRAS Molecuar Target Drugs and Future Prospects: Report
Drs. Fuyuhiko Tamanoi, Hideyuki Saya, Toshio Imai, and Kiyoko Kato present a report of the online meeting that they organized, titled “Development of mutant KRAS molecular target drugs and future prospects.”POSTED: 2/29/2024
Senescent macrophages promote oncogenic KRAS-driven lung cancer and suppress anti-tumour immunity
Senescent macrophages fuel KRAS-driven lung cancer and suppress immunity. Discover how targeting them could halt tumors before they start—and boost survival.POSTED: 2/5/2024
Inhibition of the MAPK pathway induces re-localization of membranous proteins, leading to adaptive resistance to KRAS G12C inhibitor mediated by YAP-induced MRAS
While promising and exciting, the new KRAS G12C inhibitors have been met with unknown mechanisms of resistance. Here, Yuta Adachi and Hiromichi Ebi describe their work uncovering a non-genetic resistance mechanism involving the mis-localization of scribble, which induces YAP-mediated MRAS expression and reactivates MAPK signaling.POSTED: 11/1/2023
New type of bifunctional molecules perturb K-Ras interactions with membranes
Drs. Kevan Shokat and Johannes Morstein and describe their new and unique bifunctional drugs that bind to both KRAS and the plasma membrane.POSTED: 9/28/2023
Looking for more?
Explore our scientific publications
Our researchers publish hundreds of papers each year in various peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine.